1-3 of 3
Deborah A. Mulford, MD
Close
Sort by
Journal Articles

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Shuo Ma, MD PhD, Clive S. Zent, MD, Andrea M. Baran, MS, Andrew Bui, Philip J Meacham, PhD, Ashley Morrison, RN, Kelsey Holkovic, RN, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P. Miskin, MSc, Michael S. Weiss, Jonathan W. Friedberg, MD MSSc, Brian T. Hill, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-134818
Published: 2020
Journal Articles

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Brian T. Hill, MD, Shuo Ma, MD PhD, Andrea M Baran, MS, Andrew Bui, Philip J Meacham, MS, Ashley Morrison, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S Weiss, Jonathan W. Friedberg, MD, Clive S Zent, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 360.
https://doi.org/10.1182/blood-2019-123404
Published: 2019
Journal Articles

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Todd Rosenblat, MD, MS, Michael R. McDevitt, PhD, Deborah A. Mulford, MD, Neeta Pandit-Taskar, MD, Mark A. Weiss, MD, Mark L. Heaney, MD, PhD, Suzanne Chanel, RN, Alfred Morgenstern, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD
Journal: Blood
Blood (2008) 112 (11): 2983.
https://doi.org/10.1182/blood.V112.11.2983.2983
Published: 2008